Welldoc AI Cardiometabolic Digital Health Platform

Welldoc, Inc. is a US-headquartered digital health company led by CEO and President Kevin McRaith, with a Center for Innovation, Development and Research in Bangalore, India. It focuses on cardiometabolic conditions such as diabetes, hypertension and obesity, where patient data is scattered across devices, apps and clinical systems.

The Welldoc platform turns that data into personalised coaching for members and insights for care teams and partners. Welldoc Diabetes and Welldoc Diabetes Rx are FDA-cleared for adults with type 1 or type 2 diabetes, and the platform also covers weight management, hypertension and complex conditions. It connects to 400+ devices and data sources, including CGMs, scales and cuffs, and is sold to life sciences and medtech firms, health plans, PBMs, employers and health systems.

• FDA-cleared diabetes software: Welldoc Diabetes and Diabetes Rx for type 1 and type 2 adults.
• Cardiometabolic programmes: weight management, hypertension and combined condition support.
• AI insights: analysis of 500M+ metrics across 80+ health domains per user each year.
• Device connectivity: integration with 400+ devices and data sources including CGMs.
• Care team loop: daily health data routed to clinicians for timely action.
• Partner programmes: solutions delivered through life sciences, medtech, payer and employer partners.

Pharma companies in Vietnam could license the platform to support patients on diabetes or obesity therapies. Device distributors selling CGMs and blood pressure monitors could add a connected coaching layer. Private insurers could offer cardiometabolic programmes to members with chronic conditions.

Holds 11 FDA 510(k) clearances, giving partners a regulated foundation for diabetes products. Backed by 100+ clinical publications and 69 patents. Covers 53 million lives through partners, showing it can scale with large payers. Connects 400+ devices so partners can reuse existing CGMs, meters and cuffs.

Pharma and medtech companies are pairing drugs such as GLP-1s and devices such as CGMs with software that keeps patients engaged and generates real-world evidence. Payers want one cardiometabolic platform rather than separate point solutions. In Asia, including Vietnam, the fast rise of diabetes and hypertension is pushing insurers and pharma toward similar digital companion programmes.

Welldoc, Inc. has US headquarters and an R&D centre in Bangalore, India; CEO Kevin McRaith. Partners include Abbott, CVS Health, Eli Lilly, Astellas, Dexcom and Databricks. Named a Top 50 Healthcare Technology Company 2025 and holds Great Place to Work certification for 2026-2027.